ZA201906580B - Novel compounds and therapeutic uses thereof - Google Patents

Novel compounds and therapeutic uses thereof

Info

Publication number
ZA201906580B
ZA201906580B ZA2019/06580A ZA201906580A ZA201906580B ZA 201906580 B ZA201906580 B ZA 201906580B ZA 2019/06580 A ZA2019/06580 A ZA 2019/06580A ZA 201906580 A ZA201906580 A ZA 201906580A ZA 201906580 B ZA201906580 B ZA 201906580B
Authority
ZA
South Africa
Prior art keywords
novel compounds
compounds
therapeutic uses
novel
ability
Prior art date
Application number
ZA2019/06580A
Other languages
English (en)
Inventor
Michael Westby
Melanie Glossop
Christine Watson
Christopher Pickford
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of ZA201906580B publication Critical patent/ZA201906580B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2019/06580A 2017-04-07 2019-10-07 Novel compounds and therapeutic uses thereof ZA201906580B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1705686.2A GB201705686D0 (en) 2017-04-07 2017-04-07 Novel compounds and therapeutic uses thereof
PCT/GB2018/050928 WO2018185495A1 (en) 2017-04-07 2018-04-06 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ZA201906580B true ZA201906580B (en) 2024-01-31

Family

ID=58744828

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/06580A ZA201906580B (en) 2017-04-07 2019-10-07 Novel compounds and therapeutic uses thereof

Country Status (12)

Country Link
US (1) US11766483B2 (https=)
EP (1) EP3606561B1 (https=)
JP (2) JP7695773B2 (https=)
KR (1) KR102646581B1 (https=)
CN (1) CN110753558B (https=)
AU (1) AU2018248706B2 (https=)
CA (1) CA3059018A1 (https=)
ES (1) ES2954294T3 (https=)
GB (1) GB201705686D0 (https=)
IL (1) IL270460B2 (https=)
WO (1) WO2018185495A1 (https=)
ZA (1) ZA201906580B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034957A1 (en) * 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
FR2801305B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
FI20011664L (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
EP2322209A3 (en) 2002-08-20 2012-02-01 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
US7585886B2 (en) * 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
WO2009108807A1 (en) 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides and methods of making and using them
JP2011519049A (ja) * 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US10017481B2 (en) * 2012-03-17 2018-07-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
WO2013166110A1 (en) * 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
EP3160513B1 (en) * 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof
MX2019002879A (es) * 2016-09-13 2019-09-18 Centauri Therapeutics Ltd Compuestos novedosos y usos terapeuticos de los mismos.

Also Published As

Publication number Publication date
US20200147236A1 (en) 2020-05-14
AU2018248706A1 (en) 2019-11-07
EP3606561B1 (en) 2023-08-02
JP7695773B2 (ja) 2025-06-19
US11766483B2 (en) 2023-09-26
CN110753558A (zh) 2020-02-04
WO2018185495A1 (en) 2018-10-11
AU2018248706B2 (en) 2022-04-07
GB201705686D0 (en) 2017-05-24
JP2020516613A (ja) 2020-06-11
IL270460A (https=) 2019-12-31
KR20200018402A (ko) 2020-02-19
IL270460B2 (en) 2023-09-01
KR102646581B1 (ko) 2024-03-13
IL270460B1 (en) 2023-05-01
CA3059018A1 (en) 2018-10-11
CN110753558B (zh) 2023-10-24
JP2023100679A (ja) 2023-07-19
EP3606561A1 (en) 2020-02-12
EP3606561C0 (en) 2023-08-02
ES2954294T3 (es) 2023-11-21

Similar Documents

Publication Publication Date Title
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
ZA202311311B (en) Anti-bcma heavy chain-only antibodies
MX2022007522A (es) Anticuerpos anti-cd27.
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
MD4733B1 (ro) Anticorpi anti-TIGIT
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
WO2017030823A3 (en) Anti-tigit antibodies
TW201613901A (en) New compounds
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
MX2019014876A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2024001617A (es) Composiciones biofarmaceuticas.
TN2016000435A1 (en) Novel macrocyclic compounds.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2019002879A (es) Compuestos novedosos y usos terapeuticos de los mismos.
PH12017501872A1 (en) Methods of treating diseases
ZA201906580B (en) Novel compounds and therapeutic uses thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
JOP20200090A1 (ar) عملية لتحضير بنزوثيوفين-2 يل بورونات
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.